CSIR Begins Phase-II Trial For Using Niclosamide - A Drug To Treat Tapeworm Infection As Covid-19 Remedy

CSIR in collaboration with Laxai Life Sciences has initiated Phase-II clinical trial with anti-helminitic drug Niclosamide for treatment of Covid-19. The trial is a multi-centric, phase-II, randomised, open label clinical study to evaluate efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized Covid-19 patients.

Niclosamide has been extensively used in past for treatment of tapeworm’s infection in adults as well as children. The safety profile of this drug has been tested over time and has been found safe for human consumption at different dose levels.

Dr Ram Vishwakarma, Advisor to DG-CSIR has pointed out that in a screen to identify drugs that can inhibit syncytia formation, Niclosamide was identified as a promising repurposed drug by research group from King’s College, London, who collaborated in this project.

The syncytia or fused cells observed in the lungs of patients with COVID-19 probably results from the fusogenic activity of the SARS-CoV-2 spike protein and Niclosamide can inhibit syncytia formation.

The Active Pharmaceutical Ingredient (API) is being made by Laxai Life Sciences based on improved technology developed at IICT and the lab is a partner in this important clinical trial which could provide cost effective therapeutic options for patients if trial is successful.

Having received approval from drug regulator, the clinical trial has been initiated this week at different sites and is expected that the trial will be completed within 8-12 weeks.

Based on successful clinical evidence generated during clinical trials in Indian studies, emergency use authorization may be sought so that more treatment options are available to COVID-19 patients.